Daily brief   for adults 50+ Subscribe AM & PM email
50 Plus HubEverything for Everyone 50+
Customize ➞ My age is in the: 50s 60s 70s 80+ Text size Language
‹ Back to Breaking News
health50+

An Experimental Alzheimer's Drug Showed Stronger Benefit at Two Years, but the Numbers Call for Caution

Saturday, November 21, 2026 · 2 sources

An experimental drug called diranersen showed hopeful two-year results in a study of people with early Alzheimer's disease, including about a 54 percent slowing of decline on one thinking test for its best-performing dose. The program had earlier missed its main goal, the drug is still experimental, and the two-year numbers come from a study design that calls for some caution.

A treatment aimed at slowing Alzheimer's disease drew attention this week, with results that were hopeful but mixed. Its maker, the drug company Biogen, released two-year data on November 17 from a study called CELIA, a Phase 2 trial in people with early Alzheimer's disease. The findings were presented at a medical conference on Alzheimer's research, and the trial was co-led by scientists at University College London.

What sets the drug, called diranersen, apart is how it works. Most recently approved Alzheimer's medicines attack a sticky protein called amyloid. This drug instead targets tau, a different protein that forms tangles inside brain cells and is closely tied to memory loss. It uses gene-silencing technology to lower how much tau the brain makes, and it is given through a lumbar puncture, a needle placed into the fluid around the lower spine.

The regimen that worked best was 60 mg given twice a year. Biogen reported that in that group, decline on a thinking test known as ADAS-Cog was slowed by about 54 percent at two years, up from about 42 percent at 18 months. On the Clinical Dementia Rating Sum of Boxes, a measure of memory and daily function, decline was slowed by about 38 percent at two years, up from about 26 percent at 18 months. Biogen said the benefit appeared to grow stronger over time.

How the comparison was built matters here. The two-year numbers came from an open-label extension of the study. The comparison group was made up of 115 participants who had first been assigned to a placebo and who, by the two-year mark at week 96, had received either no diranersen or a single dose. That is a weaker design than a strict head-to-head test against a placebo over the full two years, so the two-year figures should be read with some caution.

There is an important catch. In its earlier main readout, the study did not meet its primary goal, which was to show a dose-response relationship, meaning higher doses would be expected to slow decline more than lower ones. That relationship was not established.

Biogen said the drug was generally well tolerated through two years, with no new safety concerns. Diranersen is still experimental and is not available to patients. Biogen said the results give it confidence to move the drug into a larger, final-stage study, which would be needed to confirm the findings. Families can ask a doctor about treatments available now and about clinical trials.

The 50+ takeaway: Written for 50PlusHub readers from the cited sources.

Go Deeper

What did the two-year results show?

Biogen reported that in the 60 mg twice-a-year group, decline on a thinking test called ADAS-Cog was slowed by about 54 percent at two years, up from about 42 percent at 18 months. On the Clinical Dementia Rating Sum of Boxes, a measure of memory and daily function, decline was slowed by about 38 percent at two years, up from about 26 percent at 18 months.

Why should the two-year numbers be read with caution?

Two reasons. The two-year figures came from an open-label extension. The comparison group was 115 people who had first been assigned to a placebo and who, by the two-year mark at week 96, had received either no diranersen or a single dose. That is weaker than a strict test against a placebo over the full two years. And in its earlier main readout, the study missed its primary goal, which was to show that higher doses slow decline more than lower ones.

How is this drug different from other treatments?

Most recently approved drugs attack a protein called amyloid. Diranersen instead targets tau, a protein that forms tangles inside brain cells, and it uses gene-silencing technology to lower how much tau the brain makes.

How is it given, and was it safe?

The best-performing version was given twice a year through a lumbar puncture, a needle placed into the fluid around the lower spine. Biogen said the drug was generally well tolerated through two years, with no new safety concerns reported.

Can patients get this drug now?

No. Diranersen is still experimental and not approved. Biogen said it plans to move the drug into a larger, final-stage study, which would be needed to confirm the results before it could be used in everyday care.